2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. Phospholipase
  5. PLD Isoform

PLD

Phospholipase D (PLD) is a phospholipid-hydrolyzing enzyme that primarily converts phosphatidylcholine into phosphatidic acid (PA) and choline, thereby generating a key lipid second messenger involved in cellular signaling networks[1][2]. Mechanistically, PA produced by PLD regulates multiple biological processes, including vesicular trafficking, exocytosis, autophagy, cellular metabolism, and stress-responsive signaling pathways, and can further influence downstream effectors such as mTOR and Akt signaling cascades[2][3]. Through these functions, PLD contributes to the control of cell migration, membrane dynamics, endocytosis, cytoskeletal remodeling, and secretory processes that are essential for normal cellular homeostasis[1][4]. Disease relevance is supported by evidence linking altered PLD activity or expression to tumor growth, metastasis, neurodegeneration, thrombotic disorders, inflammation, diabetes, and other pathological conditions characterized by dysregulated signaling and membrane trafficking[1][4]. Compared with related isoforms, mammalian PLD1 and PLD2 share conserved catalytic domains but differ in regulatory architecture, subcellular localization, and basal activity, with PLD1 containing a unique internal regulatory loop and requiring stronger activation by regulatory proteins, whereas PLD2 exhibits higher constitutive activity and distinct membrane-associated regulation[1][5]. For experimental applications, the availability of isoform-selective small-molecule PLD inhibitors has enabled mechanistic dissection of PLD1- and PLD2-dependent signaling pathways and has strengthened the evaluation of PLD as a therapeutic target in cancer and other diseases[1].

PLD Related Products (11):

Cat. No. Product Name Effect Purity
  • HY-12807
    FIPI
    		Inhibitor 98.00%
    FIPI is a phospholipase D (PLD) inhibitor with an IC50 for PLD1 and PLD2 of about 25 nM. FIPI regulates cytoskeletal recombination, cell diffusion and chemotaxis. FIPI can be used in cancer research. In addition, FIPI can enhance the secretion and aggregation of platelet dense particles, inhibit thrombosis, reduce ischemic stroke infarct volume and improve nerve function.
  • HY-101293
    VU0359595
    		Inhibitor 98.06%
    VU0359595 (CID-53361951; ML-270) is a potent and selective pharmacological phospholipase D1 (PLD1) inhibitor with an IC50 of 3.7 nM. VU0359595 is >1700-fold selective for PLD1 over PLD2 (IC50 of 6.4 μM). VU0359595 can be used for the research of cancer, diabetes, neurodegenerative and inflammatory diseases.
  • HY-108612
    VU0155069
    		Inhibitor 98.55%
    VU0155069 (CAY10593), is a selective phospholipase D1 (PLD1) inhibitor with an IC50 value of 46 nM in vitro. VU0155069 (CAY10593) strongly inhibits the invasive migration of several cancer cell lines in transwell assays.
  • HY-P1341
    OXA(17-33)
    		Activator
    OXA (17-33) (Orexin A (17-33) (human, mouse, rat, bovine)) is the shortest active orexin peptide that selectively targets OX1 (EC50=8.29 nM), with 23-fold selectivity for the OX1 receptor over the OX2 receptor. The activity of OXA (17-33) depends on the Tyr17, Leu20, Asn25, His26 residues and the spatial conformation of the α-helix. OXA (17-33) activates signaling pathways involving inositol-1,4,5-trisphosphate receptor (IP3R), phospholipase D (PL-D) and choline-Sigma-1R, thereby increasing the cytoplasmic Ca2+ level in nucleus accumbens neurons, an effect that is blocked by Sigma-1R antagonists. OXA (17-33) serves as an important biological probe for investigating the function of the OX1 receptor. OXA (17-33) can be modified via incorporation of mixed disulfide bonds of homocysteine and cysteamine, and is widely used in studies related to insomnia and narcolepsy.
  • HY-155774
    VU533
    		99.84%
    APE-PLD (VU533) activator is a potent NAPE-PLD activator with an EC50 value of 0.30 µM. NAPE-PLD activator (VU533) can enhance NAPE-PLD activity and increase efferocytosis by macrophages. NAPE-PLD activator (VU533) can be used for cardiometabolic diseases research.
  • HY-119093
    Halopemide
    		Inhibitor 99.65%
    Halopemide is a potent phospholipase D (PLD) inhibitor, with IC50s of 220 and 310 nM for human PLD1 and PLD2, respectively. Halopemid is a dopamine receptors antagonist, and acts a psychotropic agent.
  • HY-155342
    A3373
    		Inhibitor 99.57%
    A3373, a novel chemical inhibitor of Phospholipase D1 (PLD1) and PLD2, with IC50 of 325 nM and 15.15?μM, respectively, inhibits LPS-induced immune response and plays important roles in autoimmune arthritis, bone demineralization and osteoclastogenesis.
  • HY-114095
    BML-280
    		Inhibitor 99.64%
    BML-280 (VU0285655-1) is a potent and selective phospholipase D2 (PLD2) inhibitor. BML-280 has the ability to prevent caspase-3 cleavage and reduction in cell viability induced by high glucose. BML-280 can be used for rheumatoid arthritis research.
  • HY-108616
    VU 0364739 hydrochloride
    		Inhibitor
    VU 0364739 hydrochloride is a highly selective phospholipase D2 (PLD2) inhibitor with IC50s of 20 and 1500 nM for PLD2 and PLD1, respectively. VU 0364739 hydrochloride induces apoptosis and it can be used for cancer research.
  • HY-12807A
    FIPI hydrochloride
    		Inhibitor
    FIPI hydrochloride is a phospholipase D (PLD) inhibitor with an IC50 for PLD1 and PLD2 of about 25 nM. FIPI hydrochloride regulates cytoskeletal recombination, cell diffusion and chemotaxis. FIPI hydrochloride can be used in cancer research. In addition, FIPI hydrochloride can enhance the secretion and aggregation of platelet dense particles, inhibit thrombosis, reduce ischemic stroke infarct volume and improve nerve function.
  • HY-108612A
    VU0155069 hydrochloride
    		Inhibitor
    VU0155069 hydrochloride (CAY10593 hydrochloride) is a potent selective phospholipase D (PLD) inhibitor. The IC50 values for PLD1 and PLD2 are 46 and 933 nM, respectively. VU0155069 hydrochloride inhibits migration of human and mouse breast cancer cell lines.